Upload
floyd-arthur
View
71
Download
0
Embed Size (px)
Citation preview
Clemastine Fumarate Partially Reverses Vision Loss From MS
By Floyd Arthur
A new study from the University of California San Francisco shows that the
antihistamine clemastine fumarate (Tavist) partially reverses vision loss associated
with relapsing–remitting MS. Led by Dr. Ari Green of the Multiple Sclerosis Center at
UCSF, the study compared the effects of clemastine fumarate to placebo in 50
participants with MS and persistent optic neuropathy.
The researchers will present their findings at the American Academy of Neurology's
68th Annual Meeting in Vancouver, British Columbia this week.
Optic Neuritis and MS
Vision changes and pain associated with optic neuritis are a common and early sign of
multiple sclerosis, and are often the first symptom for which MS sufferers seek medical
care. The most commonly experienced visual disturbances include red-green color
blindness, diplopia, and partial or complete blindness in one eye. These are usually
accompanied by eye pain exacerbated by eye movement, peripheral and central visual
field disturbances and diminished pupillary response to light.
Optic neuritis is caused by demyelinating inflammatory changes in the optic nerve. It is
the presenting symptom in about 20 percent of MS diagnoses and affects about 50
percent of all patients with MS.
Treatment with high-dose intravenous methylprednisolone followed by an oral
prednisone taper usually results in rapid resolution of symptoms, but has not proven to
be of benefit in long term recovery of visual acuity.
Clemastine Fumarate Shows Promise
All participants in the five-month long UCSF study had chronic stable optic neuropathy
with long-term loss of visual acuity. Average age of participants was 40 years, and the
average duration of MS symptoms was five years.
The researchers used visual evoked potential as a measure of vision loss; included study
participants had a minimum transmission delay of at least 118 milliseconds -- a
biomarker for myelin loss.
For the first three months of the study, participants were randomized to either clemastine fumarate
or placebo. For the second two months, the study groups were reversed.
At the end of the study, transmission delay in patients receiving clemastine fumarate
was reduced by slightly less than 2 milliseconds per patient in each eye. Although
modest, the improvements are considered an indicator of myelin regrowth. Said Dr.
Green, “This study is promising because it is the first time a drug has been shown to
possibly reverse the damage done by MS. Findings are preliminary,” he added, “but this
study provides a framework for future MS repair studies and will hopefully herald
discoveries that will enhance the brain's innate capacity for repair."
Clemastine fumarate is a H1 histamine agent.The major side effect experienced by study
participants was fatigue.
Visit www.Carmoongroup.com for FREE 30-Minute Consultation!